{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:24:53Z","timestamp":1786958693121,"version":"build-2736575974"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is a subtype of breast cancer associated with a poor prognosis; conventional treatments provide limited durable benefit, and resistance commonly develops. The introduction of immune checkpoint inhibitors (ICIs) has expanded treatment options for TNBC; however, ICI monotherapy has demonstrated limited efficacy, particularly in patients with advanced disease. Radiotherapy (RT) has long played a pivotal role in the treatment of early-stage and locally advanced breast cancer, as it not only exerts direct tumoricidal effects but also remodels the tumor immune microenvironment. In recent years, increasing attention has been directed toward the potential synergistic effects of ICIs and RT. This article reviews the immunological characteristics of TNBC, the current status of ICI-based therapy, and the underlying mechanisms of resistance. It also summarizes the biological rationale for combining RT with ICIs in the treatment of TNBC and, in light of recent advances in clinical research, explores the impact of different RT dose-fractionation regimens, treatment sequencing, and patient selection on therapeutic efficacy. Although current research remains in an early exploratory stage and several small studies have demonstrated the potential of this combination strategy, maximizing efficacy while controlling toxicity remains a key challenge for future clinical translation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1861526","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:31:34Z","timestamp":1786955494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing immunotherapy\u2013radiotherapy synergy in triple-negative breast cancer: mechanisms, clinical evidence, and therapeutic windows"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Bai","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Du","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Tang","sequence":"additional","affiliation":[{"name":"The First School of Clinical Medicine, Lanzhou University","place":["Lanzhou, Gansu, China"]},{"name":"Department of Radiation Oncology, The First Hospital of Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/PPO.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1872-9","article-title":"Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer","volume":"131","author":"Collins","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"B6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.clon.2011.03.013","article-title":"Metastatic triple-negative breast cancer","volume":"23","author":"Rakha","year":"2011","journal-title":"Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092392","article-title":"Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies","volume":"12","author":"Gupta","year":"2020","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1177\/2050312114551974","article-title":"The efficacy of betulinic acid in triple-negative breast cancer","volume":"2","author":"Weber","year":"2014","journal-title":"SAGE Open Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1989790","article-title":"DNMT1 constrains IFN\u03b2-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy","volume":"10","author":"Huang","year":"2021","journal-title":"OncoImmunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","article-title":"Advances in immunotherapy for triple-negative breast cancer","volume":"22","author":"Liu","year":"2023","journal-title":"Mol Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1490854","article-title":"Tumor mutational burden is a determinant of immune-mediated survival in breast cancer","volume":"7","author":"Thomas","year":"2018","journal-title":"OncoImmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz208","article-title":"Unraveling triple-negative breast cancer tumor microenvironment heterogeneity: towards an optimized treatment approach","volume":"112","author":"Bareche","year":"2020","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"JCO"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS14-PD1-6","article-title":"Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer","volume":"75","author":"Emens","year":"2015","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J immunotherapy Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1:PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab108","article-title":"PD-L1 immunohistochemistry assay comparison in atezolizumab plus nab -paclitaxel\u2013treated advanced triple-negative breast cancer","volume":"113","author":"Rugo","year":"2021","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000001053","article-title":"Tissue selection for PD-L1 testing in triple negative breast cancer (TNBC)","volume":"30","author":"Dobritoiu","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","article-title":"Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies","volume":"13","author":"Zheng","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1153990","article-title":"Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1513421","article-title":"Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review","volume":"15","author":"Serrano Garc\u00eda","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010104","article-title":"Mechanisms and strategies to overcome PD-1\/PD-L1 blockade resistance in triple-negative breast cancer","volume":"15","author":"Chen","year":"2022","journal-title":"Cancers"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","article-title":"Recent progress in immune evasion mechanisms of triple-negative breast cancer","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.388","article-title":"Double\u2010strand DNA break repair: molecular mechanisms and therapeutic targets","volume":"4","author":"Tan","year":"2023","journal-title":"MedComm"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"OncoImmunology"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245290","article-title":"Imaging calreticulin for early detection of immunogenic cell death during anticancer treatment","volume":"62","author":"Kim","year":"2021","journal-title":"J Nucl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00313","article-title":"Nanoscale metal\u2013organic frameworks for cancer immunotherapy","volume":"53","author":"Ni","year":"2020","journal-title":"Acc Chem Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.1208347","article-title":"Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice","volume":"334","author":"Michaud","year":"2011","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"OncoImmunology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00075-5","article-title":"Radiotherapy, immunity, and immune checkpoint inhibitors","volume":"25","author":"Lynch","year":"2024","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1525","article-title":"Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes","volume":"64","author":"Garnett","year":"2004","journal-title":"Cancer Res"},{"key":"B55","article-title":"Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium","volume":"56","author":"Hallahan","year":"1996","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-\u03b3 production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61931","article-title":"Suppressing T cell motility induced by anti\u2013CTLA-4 monotherapy improves antitumor effects","volume":"122","author":"Ruocco","year":"2012","journal-title":"J Clin Invest"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/1179064418761639","article-title":"The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules","volume":"11","author":"Arnold","year":"2018","journal-title":"Cancer Growth Metastasis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti\u2013CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.09.049","article-title":"Maximizing tumor immunity with fractionated radiation","volume":"83","author":"Schaue","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234","article-title":"Whole body irradiation\u2014radiobiology or medicine","volume":"26","author":"Mole","year":"1953","journal-title":"Br J Radiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.05.011","article-title":"Optimizing radiation therapy to boost systemic immune responses in breast cancer: a critical review for breast radiation oncologists","volume":"108","author":"Ho","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B69","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.semradonc.2014.07.008","article-title":"Myeloid-derived cells in tumors: effects of radiation","volume":"25","author":"Vatner","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2188196","article-title":"Challenges in the combination of radiotherapy and immunotherapy for breast cancer","volume":"23","author":"Zhang","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32599","article-title":"A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple\u2010negative breast cancer","volume":"126","author":"Ho","year":"2020","journal-title":"Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0622","article-title":"A phase 2 trial of enhancing immune checkpoint blockade by stereotactic radiation and In situ virus gene therapy in metastatic triple-negative breast cancer","volume":"28","author":"Sun","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00003","article-title":"PEARL: a phase Ib\/II biomarker study of adding radiation therapy to pembrolizumab before neoadjuvant chemotherapy in human epidermal growth factor receptor 2\u2013negative breast cancer","volume":"42","author":"Ho","year":"2024","journal-title":"JCO"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.91737","article-title":"Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: a pilot study","volume":"12","author":"Chen","year":"2023","journal-title":"eLife"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961796","article-title":"Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option","volume":"13","author":"Ren","year":"2022","journal-title":"Front Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3892\/or.9.4.683","article-title":"Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review)","volume":"9","author":"van Vulpen","year":"2002","journal-title":"Oncol Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US Food and Drug Administration Database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104648","article-title":"Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial \u2013 BREASTIMMUNE-03","volume":"85","author":"Tr\u00e9dan","year":"2026","journal-title":"Breast"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s12672-025-03172-0","article-title":"Real world feasibility of combining pembrolizumab with radiotherapy in early triple negative breast cancer","volume":"16","author":"Colciago","year":"2025","journal-title":"Discov Onc"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"JCO"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-25-0566","article-title":"Phase 1b study of Dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with select advanced solid tumors","volume":"5","author":"Cooper","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003468","article-title":"Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7040149","article-title":"Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells","volume":"7","author":"Saleh","year":"2019","journal-title":"Vaccines"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1146934","article-title":"Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer","volume":"13","author":"Kim","year":"2023","journal-title":"Front Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861526\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:31:39Z","timestamp":1786955499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1861526\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2026.1861526"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1861526","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1861526"}}